1 terminated. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Terminated 1 |
Follow Wound Healing Delayed: new trials by email Literature Review of Wound Healing Delayed trials Research Report on Wound Healing Delayed
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating Safety and Biological Effect on Wound Healing of ILP100-Topical in Subjects With Diabetic Foot Ulcers ILP100-Topical (emilimogene sigulactibac) 5x10^7 CFU/cm^2, ILP100-Topical (emilimogene sigulactibac) 1x10^9 CFU/cm^2, Placebo - Wound Heal, Wound Healing Disturbance of | Phase 2 | Terminated | Ilya Pharma | 1 | 2022-09-26 | 2025-03-05 |
Diabetic Foot (1)
Cardiovascular Diseases (1) · Diabetes Complications (1) · Diabetes Mellitus (1) · Diabetic Angiopathies (1) · Diabetic Neuropathies (1) · Endocrine System Diseases (1) · Foot Ulcer (1) · Leg Ulcer (1) · Skin Diseases (1) · Skin Ulcer (1) · Skin and Connective Tissue Diseases (1) · Vascular Diseases (1)
Ilya Pharma (1)
Sweden (1)